Document is current
Any future updates will be listed below
-
Authors
Sakuma, Masashi
Iimuro, Satoshi
Shinozaki, Tomohiro
Kimura, Takeshi
Nakagawa, Yoshihisa
Ozaki, Yukio
Iwata, Hiroshi
Miyauchi, Katsumi
Daida, Hiroyuki
Suwa, Satoru
Sakuma, Ichiro
Nishihata, Yosuke
Saito, Yasushi
Ogawa, Hisao
Matsuzaki, Masunori
Ohashi, Yasuo
Taguchi, Isao
Toyoda, Shigeru
Inoue, Teruo
Nagai, Ryozo
-
Funding
Funding for this research was provided by:
Lifestyle-Related Disease of the Public Health Research Foundation
- License Information
-
More Information
Article History
Received: 21 April 2022
Accepted: 24 October 2022
First Online: 14 November 2022
Declarations
:
: The study protocol was approved by the Public Health Research Foundation ethics review committee (CSP-LD 09) and by the ethics committees at all participating centers. All the study patients provided written informed consent. All clinical investigations were conducted according to the Declaration of Helsinki. The research has been registered at ExternalRef removed (ExternalRef removed. Unique identifier: NCT01042730).
: Not applicable.
: Yoshihisa Nakagawa, Hiroshi Iwata, Hiroyuki Daida, Ichiro Sakuma, and Ryozo Nagai received honoraria from Kowa Pharmaceutical Co, Ltd, Nagoya, Japan, the pharmaceutical company that developed pitavastatin. The other authors declare no competing interests.
